Transesophageal Echocardiography in Embolic Stroke of Undetermined Source (ETO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03107637|
Recruitment Status : Active, not recruiting
First Posted : April 11, 2017
Last Update Posted : October 18, 2018
The ESUS concept was introduced recently to describe a non-lacunar stroke of undetermined etiology. The following etiological workup is required in this setting: head CT or MRI, 12-lead ECG, transthoracic echocardiography, continuous cardiac monitoring for at least 24 hours after stroke, vascular imaging (ultrasound, magnetic resonance angiography, CT angiography, catheter angiography). Transesophageal echocardiography (TEE) is considered not to be required.
However, aortic arch atheroma as diagnosed by TEE in the setting of recent ischemic stroke is a major aortic source of embolism, as supported by numerous well conducted studies. The European Association of Echocardiography considers that TEE is the gold standard for the diagnosis and the characterization of aortic atheroma. It is also the method of choice for the diagnosis of infectious endocarditis.
The aim of this work was to evaluate the rate of patients with a therapeutic modification induced by TEE (mainly anticoagulation and surgery), in consecutive patients admitted with ESUS at our institution stroke unit.
|Condition or disease|
|Embolic Stroke of Undetermined Source Ischemic Stroke|
|Study Type :||Observational|
|Actual Enrollment :||186 participants|
|Official Title:||Therapeutic Implications of Early Transesophageal Echocardiography in Embolic Stroke of Undetermined Source (ESUS)|
|Actual Study Start Date :||October 3, 2016|
|Estimated Primary Completion Date :||January 2019|
|Estimated Study Completion Date :||January 2019|
- therapeutic modification after transesophageal echocardiography [ Time Frame: 24 hours after TEE ]proportion of patients with a therapeutic modification (mainly anticoagulation and surgery)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03107637
|Fondation Ophtalmologique A de Rothschild|
|Paris, France, 75019|
|Principal Investigator:||Nadia Benyounes, MD||Fondation Ophtalmologique A. de Rothschild|